Bulletin
Investor Alert

New York Markets Close in:

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

Market open

/zigman2/quotes/207821052/composite

$

43.54

Change

-0.31 -0.71%

Volume

Volume 540,816

Feb 7, 2023, 1:30 p.m.

Real time quotes

/zigman2/quotes/207821052/composite

Previous close

$ 43.85

$ 43.54

Change

-0.31 -0.71%

Day low

Day high

$43.40

$45.34

Open
Open: 43.96

52 week low

52 week high

$32.44

$104.06

Open

Market cap

$3.74B

Average volume

1.30M

P/E ratio

N/A

Rev. per Employee

$105,984

EPS

-5.87

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Intellia Therapeutics stock price target cut to $131 from $173 at Stifel Nicolaus

    7:49 a.m. Jan. 6, 2023

    - Tomi Kilgore

  2. Intellia Therapeutics started at overweight with $84 stock price target at Morgan Stanley

    8:41 a.m. Oct. 11, 2022

    - Tomi Kilgore

  3. What’s Next for the Healthcare Industry, and How to Invest

    8:47 a.m. Sept. 25, 2022

    - Barron's Online

  4. 11 Cheap Tech Stocks to Consider After the Earnings Deluge

    3:32 p.m. Aug. 25, 2022

    - Barron's Online

  5. 10 Stocks Driving the Biotech Resurgence

    7:49 a.m. Aug. 18, 2022

    - Barron's Online

  6. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    3:25 p.m. June 23, 2022

    - Barron's Online

  7. Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital

    11:22 a.m. June 17, 2022

    - Tomi Kilgore

  8. Intellia Therapeutics upgraded to outperform from perform at Oppenheimer

    7:28 a.m. Feb. 7, 2022

    - Tomi Kilgore

  9. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  10. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  11. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    6:37 a.m. Sept. 27, 2021

    - Barron's Online

  12. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    6:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. IDNA: Healthcare Dashboard For November

    12:26 p.m. Nov. 16, 2022

    - Seeking Alpha

  2. ARKK Bears Are Losing Momentum

    8:04 p.m. Nov. 13, 2022

    - Seeking Alpha

  3. Intellia Therapeutics (NTLA) Investor Presentation - Slideshow

    11:30 p.m. Nov. 9, 2022

    - Seeking Alpha

  4. Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

    12:20 p.m. Nov. 4, 2022

    - Zacks.com

  5. Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch

    6:45 a.m. Nov. 4, 2022

    - Seeking Alpha

  6. Prime Medicine: CRISPR 3.0 Company

    6:52 p.m. Oct. 24, 2022

    - Seeking Alpha

  7. RGA Investment Advisors Q3 2022 Investment Commentary

    10:45 a.m. Oct. 23, 2022

    - Seeking Alpha

  8. GNOM: ETF Review And Healthcare Dashboard For October

    6:01 p.m. Oct. 15, 2022

    - Seeking Alpha

  9. Loading more headlines...
/news/pressrelease/company/us/ntla

Press Releases on NTLA

  1. Loading more headlines...

Rates »

Link to MarketWatch's Slice.